Location of Involved Regions Rated as Malignant in Both Staging and Restaging Cohorts
| Location | 68Ga-PSMA-11 PET | 18F-rhPSMA-7 PET | ||
|---|---|---|---|---|
| Patients | Involved regions | Patients | Involved regions | |
| Patients with suggestive lesions | 124/160 (77.5%) | 189 | 123/160 (76.9%) | 187 |
| Local | 65/160 (40.6%) | 65/189 (34.4%) | 75/160 (46.9%) | 75/187 (40.1%) |
| Lymph node metastases | 78/160 (48.8%) | 95/189 (50.3%) | 61/160 (38.1%) | 76/187 (41.1%) |
| Pelvic | 65 | 55 | ||
| Extrapelvic | 30 | 21 | ||
| Bone metastases | 28/160 (17.5%) | 28/189 (14.8%) | 30/160 (18.8%) | 30/187 (16.0%) |
| Other metastases | 1/160 (0.6%) | 1/189 (0.6%) | 6/160 (3.8%) | 6/187 (3.2%) |
Data are number followed by percentage in parentheses.